SFRP2 and Myocardial fibrosis: In fact, although Sfrp2 has traditionally been considered a Wnt inhibitor, its activation has been associated with the increase in the activity of β-catenin pathways, which in the heart of diabetic rats, could have triggered the activation of β-catenin, leading to increased myocardial fibrosis [39].